Big Pharmas eye Stiefel Labs buy

A deal a day keeps boredom away. Thank goodness, then, for Stiefel Laboratories. The dermatology drug specialist has put itself up for sale, and more than one big-name pharma firm is interested. The deal could be worth several billion dollars.

Among the tire kickers are Johnson & Johnson, Novartis and GlaxoSmithKline, sources told the Wall Street Journal. The sources also said that Stiefel is looking for $3 billion to $4 billion. The company, however, won't confirm that it's even soliciting offers. "Like any business, if we received an offer it would be carefully considered," a spokeswoman said.

Here's some company background: For more than 160 years, the Stiefel family has controlled the company, which makes anti-itch creams, acne treatments, and other skin remedies. Blackstone Group, the private-equity firm, invested about half a billion in the company in 2007, in return for a "substantial" minority stake. Some media reports say Blackstone is traffic-copping the potential sale.

Why would a J&J or Glaxo want Stiefel? Diversification, for one thing. And dermatology treatments, the WSJ points out, are hot because of the aging global population and ongoing interest in looking young.

- read the Journal story

Suggested Articles

Imbruvica has enjoyed a nice run in previously untreated CLL over the last few years. But major competition is here in the form of AZ's Calquence.

Pennsylvania's Supreme Court revived thousands of lawsuits alleging the antipsychotic med Risperdal caused males to develop breasts.

In the asthma biologics race, there doesn't appear to be a clear favorite among Xolair, Dupixent, Fasenra and Nucala for a group of pulmonologists.